Pharmaceuticals Analysts discuss novel treatments and clinical trial design innovations in focal onset epilepsy (RAPP, XENE, NPCE) on an Analyst/Industry conference call to be held on July 10.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Rapport Therapeutics files to sell 470,589 shares of common stock for holders
- Rapport Therapeutics files $400M mixed securities shelf
- Rapport Therapeutics Elects New Directors at Annual Meeting
- Rapport Therapeutics management to meet with Citizens JMP
- Rapport Therapeutics Completes Enrollment for Phase 2a Trial